Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease



Status:Recruiting
Conditions:Alzheimer Disease
Therapuetic Areas:Neurology
Healthy:No
Age Range:60 - 75
Updated:10/6/2018
Start Date:May 2014
End Date:December 2018
Contact:Danielle Kemeny
Email:cbhresearch@ccf.org
Phone:216-445-9009

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
This 24-week study will examine the sensitivity of functional MRI to detect brain changes
caused by donepezil HCL (a cholinesterase inhibitor) in healthy older adults at genetic risk
for Alzheimer's Disease. Participants with a family history of Alzheimer's Disease will be
eligible for this study. Participants without a family history of AD will also be enrolled to
serve as a control group.


Inclusion Criteria:

- Normal general cognitive function

- High Risk Group Only: Family history (1st degree relative) of AD

- Low Risk Group Only: No family history (1st or 2nd degree relative) of AD

- Visual and auditory acuity adequate for neuropsychological testing

Exclusion Criteria:

- Current or past history of

- neurological illnesses/conditions

- head trauma with significant loss of consciousness

- medical illnesses/conditions that may affect brain function

- severe psychiatric disorder

- substance abuse

- unstable or severe cardiovascular disease or asthmatic condition

- history of stroke or transient ischemic attack
We found this trial at
1
site
Cleveland Clinic Center for Brain Health
Cleveland, Ohio 44195
Principal Investigator: Stephen M Rao, PhD
?
mi
from
Cleveland, OH
Click here to add this to my saved trials